Clinical Trials Logo

Episodic Migraine clinical trials

View clinical trials related to Episodic Migraine.

Filter by:

NCT ID: NCT05042037 Recruiting - Migraine Clinical Trials

Probiotics as Adjunctive Migraine Prophylaxis

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

This study will assess the safety and efficacy of multi-strain probiotics as an adjunctive treatment for episodic migraine

NCT ID: NCT04828941 Recruiting - Migraine Disorders Clinical Trials

My Healthy Diary - An Electronic Diary for Remote Migraine Monitoring

E-Migra
Start date: March 28, 2021
Phase: N/A
Study type: Interventional

This study aims to evaluate the usefulness of an app-based headache diary in episodic migraine patients. For this the investigators will conduct a randomized clinical trial with a crossover design, using the app-based diary and a traditional paper-based headache diary. The patients will use each diary for 13 weeks. The investigators will evaluate diary adhesion after each 13-week period, and also evaluate headache burden and prophylactic medication compliance at the beginning, at the crossover point, and at the end of the study, and acute headache medication use through diary records. The investigators will also evaluate user preference through a questionnaire at the end of the study.

NCT ID: NCT04628429 Recruiting - Chronic Migraine Clinical Trials

CGRP Inhibition, Autonomic Function, and Migraine

CGRP-1
Start date: October 1, 2020
Phase:
Study type: Observational

The purpose of this clinical study is to better understand the function of the autonomic nervous system in patients with migraine. We aim to understand whether the autonomic functions change depending on the migraine status (i.e. whether they are between or during attacks) and whether the CGRP monoclonal antibody (mAb) class of drugs affects the autonomic functions. The aim is not to investigate the effect of CGRP-mAb on migraine frequency. Calcitonin gene-related peptide (CGRP) is a neurotransmitter in the nervous system that plays an essential role in the development of migraine headache. Monoclonal antibodies can block the function of this messenger substance. Several studies have shown that this blockade leads to a reduction in the frequency of migraine. In addition to its role in migraine, CGRP also acts on the blood vessels and the autonomic nervous system. The autonomic nervous system is responsible for everything we have no control over in our body. This includes everything from heart rate and blood pressure to our digestion.

NCT ID: NCT03432286 Recruiting - Episodic Migraine Clinical Trials

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

REBUILD-1
Start date: March 14, 2018
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.